Monthly Prescribing Reference

Otezla Approved for Pediatric Patients With Plaque Psoriasis

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...
Seeking Alpha

OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS

THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (AMGN) today announced Otezla ® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug ...
Monthly Prescribing Reference

Otezla Now Approved for Plaque Psoriasis Across All Severities

The approval was based on data from the phase 3 ADVANCE trial. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) to include treatment of plaque psoriasis across ...
Seeking Alpha

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023

THOUSAND OAKS, Calif., May 30, 2023 /PRNewswire/ -- Amgen (AMGN) today announced new research examining the use of Otezla ® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and ...
Business Wire

Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla ® (apremilast)

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 ...